1392 related articles for article (PubMed ID: 8615665)
21. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
[TBL] [Abstract][Full Text] [Related]
22. Immunophenotypic characterization of infiltrating polynuclear and mononuclear cells in childhood brain tumors.
Bodey B; Bodey B; Siegel SE
Mod Pathol; 1995 Apr; 8(3):333-8. PubMed ID: 7617661
[TBL] [Abstract][Full Text] [Related]
23. In situ analysis of the mononuclear cell infiltrate in primary malignant melanoma of the skin.
Poppema S; Bröcker EB; de Leij L; Terbrack D; Visscher T; Ter Haar A; Macher E; Thé TH; Sorg C
Clin Exp Immunol; 1983 Jan; 51(1):77-82. PubMed ID: 6219841
[TBL] [Abstract][Full Text] [Related]
24. T-cell distribution and adhesion receptor expression in metastatic melanoma.
Weishaupt C; Munoz KN; Buzney E; Kupper TS; Fuhlbrigge RC
Clin Cancer Res; 2007 May; 13(9):2549-56. PubMed ID: 17473183
[TBL] [Abstract][Full Text] [Related]
25. A new Mr 55,000 surface protein implicated in melanoma progression: association with a metastatic phenotype.
Boukerche H; Baril P; Tabone E; Bérard F; Sanhadji K; Balme B; Wolf F; Perrot H; Thomas L
Cancer Res; 2000 Oct; 60(20):5848-56. PubMed ID: 11059782
[TBL] [Abstract][Full Text] [Related]
26. Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions.
Natali PG; Hamby CV; Felding-Habermann B; Liang B; Nicotra MR; Di Filippo F; Giannarelli D; Temponi M; Ferrone S
Cancer Res; 1997 Apr; 57(8):1554-60. PubMed ID: 9108459
[TBL] [Abstract][Full Text] [Related]
27. [A malignus melanoma immunterápiájának lehetoségei].
Ladányi A
Magy Onkol; 2003; 47(1):113-7. PubMed ID: 12704464
[TBL] [Abstract][Full Text] [Related]
28. [Expression of HLA-class II antigens in malignant melanoma].
Nakamura T; Matsuno M; Kageshita T; Arao T
Nihon Hifuka Gakkai Zasshi; 1990 Jan; 100(1):49-56. PubMed ID: 2191157
[TBL] [Abstract][Full Text] [Related]
29. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
[TBL] [Abstract][Full Text] [Related]
30. PUMA expression is significantly reduced in human cutaneous melanomas.
Karst AM; Dai DL; Martinka M; Li G
Oncogene; 2005 Feb; 24(6):1111-6. PubMed ID: 15690057
[TBL] [Abstract][Full Text] [Related]
31. Inverse correlation between expression of HLA-B and c-myc in uveal melanoma.
Blom DJ; Mooy CM; Luyten GP; Kerkvliet S; Ouwerkerk I; Zwinderman AH; Schrier PI; Jager MJ
J Pathol; 1997 Jan; 181(1):75-9. PubMed ID: 9072006
[TBL] [Abstract][Full Text] [Related]
32. Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma: frequency of expression and correlation with prognostic parameters.
Busam KJ; Iversen K; Berwick M; Spagnoli GC; Old LJ; Jungbluth AA
Mod Pathol; 2000 Apr; 13(4):459-65. PubMed ID: 10786815
[TBL] [Abstract][Full Text] [Related]
33. Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
Hofmann UB; Westphal JR; Zendman AJ; Becker JC; Ruiter DJ; van Muijen GN
J Pathol; 2000 Jul; 191(3):245-56. PubMed ID: 10878545
[TBL] [Abstract][Full Text] [Related]
34. Targeted liposomal c-myc antisense oligodeoxynucleotides induce apoptosis and inhibit tumor growth and metastases in human melanoma models.
Pastorino F; Brignole C; Marimpietri D; Pagnan G; Morando A; Ribatti D; Semple SC; Gambini C; Allen TM; Ponzoni M
Clin Cancer Res; 2003 Oct; 9(12):4595-605. PubMed ID: 14555535
[TBL] [Abstract][Full Text] [Related]
35. Coexpression of major histocompatibility complex class II with chemokines and nuclear NFkappaB p50 in melanoma: a rational for their association with poor prognosis.
Martins I; Sylla K; Deshayes F; Lauriol J; Ghislin S; Dieu-Nosjean MC; Viguier M; Verola O; Charron D; Alcaide-Loridan C; Al-Daccak R
Melanoma Res; 2009 Aug; 19(4):226-37. PubMed ID: 19574933
[TBL] [Abstract][Full Text] [Related]
36. [Immuno-diagnosis of malignant melanoma].
Szekeres G; Battyáni Z
Magy Onkol; 2003; 47(1):45-50. PubMed ID: 12704454
[TBL] [Abstract][Full Text] [Related]
37. Cell culture observations of human postnatal thymic epithelium: an in vitro model for growth and humoral influence on intrathymic T lymphocyte maturation.
Bodey B; Bodey B; Kaiser HE
In Vivo; 1996; 10(5):515-26. PubMed ID: 8899432
[TBL] [Abstract][Full Text] [Related]
38. Epithelial markers in malignant melanoma. A study of primary lesions and their metastases.
Ben-Izhak O; Stark P; Levy R; Bergman R; Lichtig C
Am J Dermatopathol; 1994 Jun; 16(3):241-6. PubMed ID: 7524376
[TBL] [Abstract][Full Text] [Related]
39. Overexpression of Lerk-5/Eplg5 messenger RNA: a novel marker for increased tumorigenicity and metastatic potential in human malignant melanomas.
Vogt T; Stolz W; Welsh J; Jung B; Kerbel RS; Kobayashi H; Landthaler M; McClelland M
Clin Cancer Res; 1998 Mar; 4(3):791-7. PubMed ID: 9533549
[TBL] [Abstract][Full Text] [Related]
40. Tumor antigen expression in melanoma varies according to antigen and stage.
Barrow C; Browning J; MacGregor D; Davis ID; Sturrock S; Jungbluth AA; Cebon J
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):764-71. PubMed ID: 16467087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
